Helmholtz Gemeinschaft


A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo

Official URL:https://doi.org/10.1073/pnas.0408936102
PubMed:View item in PubMed
Creators Name:Zhang, X. and Smith, D.L. and Meriin, A.B. and Engemann, S. and Russel, D.E. and Roark, M. and Washington, S.L. and Maxwell, M.M. and Marsh, J.L. and Thompson, L.M. and Wanker, E.E. and Young, A.B. and Housman, D.E. and Bates, G.P. and Sherman, M.Y. and Kazantsev, A.G.
Journal Title:Proceedings of the National Academy of Sciences of the United States of America
Journal Abbreviation:Proc Natl Acad Sci U S A
Page Range:892-897
Date:18 January 2005
Keywords:Genetic Disease, High-Throughput Screen, R6/2 Brain Slices, Small-Molecule Therapeutics, Animals, Drosophila, Mice
Abstract:Polyglutamine (polyQ) disorders, including Huntington's disease (HD), are caused by expansion of polyQ-encoding repeats within otherwise unrelated gene products. In polyQ diseases, the pathology and death of affected neurons are associated with the accumulation of mutant proteins in insoluble aggregates. Several studies implicate polyQ-dependent aggregation as a cause of neurodegeneration in HD, suggesting that inhibition of neuronal polyQ aggregation may be therapeutic in HD patients. We have used a yeast-based high-throughput screening assay to identify small-molecule inhibitors of polyQ aggregation. We validated the effects of four hit compounds in mammalian cell-based models of HD, optimized compound structures for potency, and then tested them in vitro in cultured brain slices from HD transgenic mice. These efforts identified a potent compound (IC 50 = 10 nM) with long-term inhibitory effects on polyQ aggregation in HD neurons. Testing of this compound in a Drosophila HD model showed that it suppresses neurodegeneration in vivo, strongly suggesting an essential role for polyQ aggregation in HD pathology. The aggregation inhibitors identified in this screen represent four primary chemical scaffolds and are strong lead compounds for the development of therapeutics for human polyQ diseases.
Publisher:National Academy of Sciences (U.S.A.)
Item Type:Article

Repository Staff Only: item control page

Open Access
MDC Library